ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

12,232Medicare Part D Prescriptions Filled, Including Refills

Rank: 265 out of 6969

$440K Total Retail Price of All Prescriptions

Rank: 787 out of 6969

720 Patients Receiving at Least One Drug in Part D
81%Patients 65 Years and Older
65% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in California
Lower avg

Schedule Two
Controlled Substances

4% of this provider’s 720 patients filled at least one prescription for a schedule two drug, compared to an average of 3%.

Schedule Three
Controlled Substances

5% of this provider’s 720 patients filled at least one prescription for a schedule three drug, compared to an average of 14%.

Risky Drugs to Seniors

2% of this provider’s 10,597 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

17% of this provider’s prescriptions were for brand-name drugs, compared to an average of 23%.

Prescription Price

$36 was the average price of a prescription from this provider, compared to $57 among peers.

Prescriptions per Patient

17 is the average number of prescriptions (including refills) per patient, compared to an average of 15.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in California
METFORMIN HCL 1,189 1,017 1 7
BENAZEPRIL HCL 646 566 2 18
OMEPRAZOLE 612 548 3 6
HYDROCHLOROTHIAZIDE 451 402 4 8
CARVEDILOL 399 356 5 25
IBUPROFEN 366 281 6 29
ALENDRONATE SODIUM 322 304 7 14
LISINOPRIL 283 253 8 2
LEVOTHYROXINE SODIUM 272 245 9 5
GABAPENTIN 271 234 10 17
METHYLPREDNISOLONE 229 191 11 225
ATENOLOL 225 188 12 9
ONGLYZA 224 199 13 164
JANUVIA 221 194 14 41
TERAZOSIN HCL 211 202 15 49
CAPTOPRIL 207 191 16 226
LOSARTAN POTASSIUM 187 181 17 12
GEMFIBROZIL 150 130 18 85
AMLODIPINE BESYLATE 134 123 19 4
SIMVASTATIN 127 85 20 1
DONEPEZIL HCL 126 126 21 32
LANTUS 126 114 21 50
TAMSULOSIN HCL 118 114 23 23
LIDOCAINE 116 74 24 336
PREDNISONE 114 94 25 70
PROMETHAZINE HCL 110 78 R 26 203
AVODART 99 94 27 108
PENTOXIFYLLINE 97 76 28 310
FUROSEMIDE 90 84 29 10
NIFEDIPINE ER 88 79 30 95
BUPROPION HCL 87 85 31 391
NIASPAN 86 73 32 146
LORATADINE 79 70 33 236
NAPROXEN SODIUM 75 72 34 358
LOVASTATIN 73 73 35 15
DIOVAN 69 64 36 26
NIFEDICAL XL 68 64 37 311
CITALOPRAM HBR 67 63 38 34
WARFARIN SODIUM 63 62 39 20
ALLOPURINOL 62 46 40 35
METOPROLOL TARTRATE 62 58 40 13
SULFAMETHOXAZOLE-TRIMETHOPRIM 60 53 42 114
CEPHALEXIN 55 48 43 96
METHOCARBAMOL 53 30 R 44 249
LEVETIRACETAM 52 48 45 128
HUMALOG 50 43 46 167
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Aug. 20, 2012.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.